Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: first report of a phase 3 trial (ALTA-1L)
Authors
Camidge, RKim, H
Ahn, M
Yang, J
Han, J
Lee, J
Hochmair, M
Li, J
Chang, G
Lee, K
Gridelli, C
Delmonte, A
Campelo, M
Kim, D
Bearz, A
Griesinger, F
Morabito, A
Felip, E
Califano, Raffaele
Ghosh, S
Spira, A
Gettinger, S
Tiseo, M
Haney, J
Kerstein, D
Popat, S
Affiliation
University of Colorado Cancer Center, Aurora, CO/USIssue Date
2018
Metadata
Show full item recordCitation
Camidge R, Kim HR, Ahn M, Yang JC, Han J, Lee J, et al. PL02.03 Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK plus NSCLC: first report of a phase 3 trial (ALTA-1L)). J Thorac Oncol. 2018;13(10):S184-S185.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2018.08.011Additional Links
https://dx.doi.org/10.1016/j.jtho.2018.08.011Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2018.08.011